Genmab A (GMAB) Free Cash Flow (2020 - 2026)

Genmab A (GMAB) has reported Free Cash Flow for 6 consecutive years, with $51.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow fell 84.4% year-over-year to $51.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 billion (down 28.92% YoY), and the FY2025 full-year result was $1.1 billion, up 170.96% from the prior year.
• Free Cash Flow grew to $51.0 million in Q2 2026 per GMAB's latest filing, from $3.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $3.2 billion in Q1 2023 and bottomed at -$4.6 billion in Q4 2023.
• Historically, Free Cash Flow has averaged $153.7 million across 4 years, with a median of $307.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow surged 31.05% in 2025, then tumbled 98.95% in 2026.
• Over 4 years, Free Cash Flow stood at -$4.6 billion in 2023, then jumped by 115.89% to $737.0 million in 2024, then rose by 20.08% to $885.0 million in 2025, then slumped by 94.24% to $51.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $51.0 million, $3.0 million, and $885.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.